POLARIS-2: Study of Olverembatinib (HQP1351) in Patients With CP-CML
Condition: Chronic Myeloid Leukemia
Sponsor: Ascentage Pharma Group Inc.
Full Title
Protocol HQP1351CG301: A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia
Study Treatment
Third-generation BCR-ABL1 tyrosine kinase inhibitor Olverembatinib vs bosutinib
Eligibility/Info
Eligible patient must have chronic phase chronic myeloid leukemia without a history of accelerated or blastic phase.
Part A: Treatment with at least two prior TKIs and confirmed absence of T315I and V229L mutations
Part B: Confirmed presence of T315I mutation, prior treatment with at least 1 TKI, and lack of other effective/tolerable therapies
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
